Clinical Trials Logo

Filter by:
NCT ID: NCT01865877 Completed - Parkinson's Disease Clinical Trials

Motor, Non-motor and Genetic Determinants of Progression in Parkinson's Disease: A Mexican Multicenter Cohort Study

ReMePARK
Start date: August 2012
Phase: N/A
Study type: Observational [Patient Registry]

The objective of the study is to assess the effect of motor, non-motor and genetic factors on the progression of Parkinson's disease as well as its impact on complications rates. A large sample of Mexican subjects with Parkinson's disease attending several referral centers will be included. Data collected will include disease severity and motor scales, non-motor scales as well as genotyping for monogenic forms of the disease. Assessments will be performed every 6 months for two years.

NCT ID: NCT01863732 Completed - Clinical trials for Spondylitis, Ankylosing

Extension in AS: Sustainability of Benefits, Safety and Tolerability

MEASURE 1 ext
Start date: November 6, 2013
Phase: Phase 3
Study type: Interventional

This 3-year extension study aims at making available the treatment with secukinumab in prefilled syringes (PFS) to patients with ankylosing spondylitis who took part in phase III study CAIN457F2305, defined as "core study", as well as to generate additional data on the sustainability of clinical benefits, safety and tolerability during long-term administration of secukinumab.

NCT ID: NCT01863615 Completed - Clinical trials for Skin Infections (Acne)

Bioequivalence Study for an Isotretinoin

Start date: August 26, 2011
Phase: Phase 1
Study type: Interventional

The objective of this study was to confirm if two formulations of isotretionin (capsules) are bioequivalent. Test product was Oratane® 20 mg (Laboratorios Dermatológicos Darier) and reference product Roaccutan® 20 mg (Productos Roche). Two capsules administered together were the single dosage. The study was prospective, open-label, randomized, crossover, single dose, with 02 treatments, 02 sequences and 02 periods, under fed conditions. The population was composed of 36 healthy volunteers, male adults between 18-45 years. The comparative bioavailability of the two formulations was evaluated based in statistical comparisons of relevant pharmacokinetic parameters, obtained from data of drug concentrations in blood.

NCT ID: NCT01862263 Terminated - Clinical trials for Type 2 Diabetes Mellitus

Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II Diabetes

VIDA
Start date: May 2013
Phase: Phase 4
Study type: Interventional

The purpose of the study is to assess if the addition of vildagliptin as add-on therapy improves glucose variability in type 2 diabetes mellitus (T2DM) patients inadequately controlled with insulin, with special emphasis in hypoglycemic episodes measured by continuous glucose monitoring.

NCT ID: NCT01860976 Completed - Psoriatic Arthritis Clinical Trials

Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis

ASTRAEA
Start date: June 17, 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare subcutaneous Abatacept to placebo in the treatment of psoriatic arthritis

NCT ID: NCT01857960 Recruiting - Acne Clinical Trials

Attitudes and Knowledge of Acne in Mexican Adolescents

Start date: May 2012
Phase: N/A
Study type: Observational

Acne is a chronic inflammatory disease that affects almost 100% of the teenagers worldwide. The peak incidence is between 12 and 18 years old, although it can be present in adults. There are many different beliefs about what can cause or exacerbate acne, and also about treatment. In Mexico, 26.4% of the population is between 15 and 29 years old, which represents that more than 25% of the population is at risk for presenting acne. In our country, the different beliefs about the causes and treatment of acne among general adolescent population have not been explored. The objective of the present study is to determine the possible causes for which young Mexicans do not go to the dermatologist to receive treatment for acne. Our main hypothesis is that the lack of knowledge of the disease is responsible for this behavior.

NCT ID: NCT01856309 Completed - Clinical trials for Arthritis, Rheumatoid

Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003

SIRROUND-LTE
Start date: August 7, 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the long-term safety and efficacy of CNTO 136 (sirukumab) in participants with rheumatoid arthritis (RA) who are unresponsive to treatment with modifying antirheumatic drugs (DMARDs) or anti-TNF alpha agents.

NCT ID: NCT01855750 Completed - Lymphoma Clinical Trials

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Start date: September 3, 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate if ibrutinib administered in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) improves the clinical outcome in newly diagnosed patients with non-germinal center B-cell subtype (GCB) of diffuse large B-cell lymphoma (DLBCL) selected by immunohistochemistry (IHC) or newly diagnosed patients with activated B cell-like (ABC) subtype of DLBCL identified by gene expression profiling (GEP) or both populations.

NCT ID: NCT01854047 Completed - Asthma Clinical Trials

An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma

Start date: June 2013
Phase: Phase 2
Study type: Interventional

Primary Objective: To evaluate the efficacy of different doses and regimens of dupilumab in patients with moderate to severe uncontrolled asthma Secondary Objective: To evaluate different doses and regimens of dupilumab in patients with moderate to severe uncontrolled asthma, with regard to: - Safety and tolerability - Dupilumab systemic exposure and anti-drug antibodies

NCT ID: NCT01851707 Completed - Clinical trials for Rheumatoid Arthritis

A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone

ASPIRA
Start date: April 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the safety and efficacy of multiple dose levels of the investigational product (study drug), IPI-145, in combination with methotrexate compared to methotrexate alone in subjects with active moderate-to-severe Rheumatoid Arthritis.